Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced a 510K submission to the FDA seeking pre-market clearance for Bovie’s BOSS for surgical applications where soft tissue bipolar coagulation is desired. The BOSS is the latest generation device based on Bovie’s saline enhanced sintered steel technology.

The BOSS delivers RF energy simultaneously with saline to perform coagulation of soft tissue and bone, with minimal smoke, charring and sticking of tissue as well as reduced blood loss. Saline enhanced surgeries reduce operating time while improving post-operative outcomes and shortens recovery time.

The BOSS will primarily be targeted towards orthopedic hip and knee reconstruction surgeries, which are significant markets, with over 1.3 million procedures performed in the United States annually. These procedures represent large and growing markets due to a more active and aging population. The worldwide market is expected to exceed $500 million in 2009.

Andrew Makrides, president of Bovie, stated, “In today’s economic environment, where controlling medical costs is important, the BOSS technology meets the needs of patients, surgeons and hospitals. Reduced blood loss, shortened operating and recovery time makes the BOSS a technology product that targets a large and growing market.”

For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie’s website www.boviemedical.com.

This document may contain some forward looking statements, particularly regarding operational prospects in 2009 and beyond, which involve a number of risks and uncertainties that could cause actual results to differ materially. These risks are listed from time to time in the Company’s SEC filings.

Buttonwood Advisory Group, Inc.
John Aneralla, 1-800-940-9087